UBS Sees Strong Sales Outlook for Eli Lilly’s Zepbound and Mounjaro
Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy.
Posts Tagged ‘NYSE:LLY’
Eli Lilly (LLY) Staring at Tremendous Opportunity in Alzheimer Market: RBC Capital Markets
Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts.
13 Best Blue Chip Stocks to Buy According to Analysts
The US equity market has recorded a stunning recovery after President Donald Trump's tariff policies sent markets on a tailspin in April.
15 Set-It-and-Forget-It Stocks to Buy According to Analysts
As expectations for trade agreements and potential rate cuts reduced investor anxiety, the S&P 500 and Nasdaq reached record closing highs on June 30, concluding their strongest...
FDA Approves Updated Label For Eli Lilly and Company (LLY)’s Amyvid To Support Alzheimer’s Diagnosis
Eli Lilly and Company (NYSE:LLY) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy.
Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy
The S&P 500 rose by 0.52% on Friday to close at a record high of 6,173.07, marking returns of 3.44% for the week, as traders looked past the termination of trade talks between...
Truist Reiterates Eli Lilly (LLY) Buy Rating on Orforglipron Diabetes Drug Data
Eli Lilly and Company (NYSE:LLY) is one of the 12 stocks that will make you rich in 10 years. On June 23, Truist Securities reiterated its “Buy” rating on Eli Lilly stock.
12 Stocks That Will Make You Rich in 10 Years
One of the most read (and recommended) books on investing is Benjamin Graham’s The Intelligent Investor.
13 Best Long Term Growth Stocks to Invest in Right Now
On June 26, Kate Moore, Citi Wealth CIO, appeared on CNBC's 'The Exchange' to talk about where the dollar markets are headed, along with the state of small and large cap trade...
Eli Lilly & Co. (LLY) is Recovering from the Period of Volatility
Macquarie Asset Management, an investment management company, released its “Macquarie Large Cap Growth Fund” first quarter 2025 investor letter.
Eli Lilly Mounjaro Sees Strong Reception in India, Rising Demand Amid Obesity, Diabetes Rates
Eli Lilly and Company (NYSE:LLY) is one of the best Fortune 500 stocks to buy according to billionaires.
Eli Lilly (LLY) Retains $1,100 Price Target at Bernstein Ahead of Diabetes Conference
Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.
12 Best Fortune 500 Stocks to Buy According to Billionaires
On June 18, Jason Hunter, JPMorgan's head of technical strategy, joined CNBC's 'Closing Bell' to discuss how he believes that there's a bias for the market to correct over the...
Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed public interest in nuclear power stocks.
What Makes Eli Lilly and Company (LLY) a Lucrative Investment?
Baron Funds, an investment management company, released its “Baron Fifth Avenue Growth Fund” first quarter 2025 investor letter.
Billionaire Stan Druckenmiller’s 10 Stock Picks with Huge Upside Potential
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital.
Adam Parker of Trivariate Research Recommends Eli Lilly’s Dividend as a Defensive Play
According to Adam Parker, founder of Trivariate Research, investors aiming for a defensive approach might want to look at select dividend-paying stocks.
UBS Maintains Price Target on Eli Lilly (LLY) Despite CVS Shift to Wegovy
Eli Lilly and Company (NYSE:LLY) is one of the 15 best stocks to invest in for an 18 year old.
Eli Lilly, Juvena Therapeutics Partner to Develop Muscle-Boosting Drugs Using AI Platform
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy for beginners now.
Eli Lilly’s Dividend May Be Small, But its Growth Tells a Bigger Story
The company’s underlying business is thriving, with analysts projecting its market value could hit $1 trillion in the coming years.
15 Best Next Generation Dividend Aristocrats to Buy
The next generation of dividend aristocrats can often be spotted through their consistent dividend growth, solid starting yields, and overall stability, even if they haven’t...
10 Best Stocks to Buy For Beginners Now
On June 12, Dan Niles, Niles Investment Management founder and portfolio manager, joined CNBC's 'Squawk Box' to discuss the state of the economy and how he expects the market ...
Goldman Sachs Remains a Buy on Eli Lilly (LLY) With an $883 Price Target
Eli Lilly and Company (NYSE:LLY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider from Goldman Sachs maintained a Buy rating on Eli Lilly...
Jim Cramer on Eli Lilly: “We Like It”
Eli Lilly and Company (NYSE:LLY) is one of the 17 stocks that Jim Cramer commented on.
11 Best Drug Stocks to Buy According to Hedge Funds
Health and Human Services Secretary Robert F. Kennedy Jr.
15 Best Stocks to Invest in for an 18 Year Old
The Bureau of Labor Statistics stated on June 11 that consumer prices increased less than anticipated in May given that President Donald Trump's tariffs had not yet had a noticeable...
Jim Cramer Commented on These 17 Stocks
On Friday, Mad Money host Jim Cramer shared his evolving view of Elon Musk’s company as he provided both praise and caution in light of recent developments involving Musk and...
Eli Lilly and Company (LLY) Surged Over Higher Expectations on its Weight Loss Pill
Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor letter.
Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company (LLY) on Business Model Mastery’s Substack. In this article, we will summarize the bulls’ thesis on LLY.
Eli Lilly (LLY)’s Target Price Slashed to $960 by TD Cowen, Reiterates Buy Rating
This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT trial.
Camurus, Eli Lilly Collaborate for Long-Acting Incretin Products Using FluidCrystal Technology
On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement.
Nxera Hits Important Milestone in Diabetes Drug Partnership with Eli Lilly
In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative diabetes and metabolic therapies, Nxera Pharma has reached...
BMO Maintains Outperform Rating on Eli Lilly (LLY), Sets $900 PT
On May 30, BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 following the company’s announcement of a...
Eli Lilly and Co. (LLY) Surged on Persistent Investor Enthusiasm
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” Q1 2025 investor letter.
Was Jim Cramer Right About Eli Lilly and Company (LLY)?
We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) ...
Did Jim Cramer Nail or Miss These 11 Stock Predictions?
During the most recent episode of Mad Money, which aired on Tuesday the 27th of May, Jim Cramer opened with a passionate defense of the artificial intelligence boom, warning viewers...
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”
We recently published a list of Jim Cramer Had These 21 Stocks on His Radar.
Eli Lilly Targets Pain Management Opportunity with SiteOne Therapeutics Acquisition
Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth opportunities.
Jim Cramer Had These 21 Stocks on His Radar
Jim Cramer, host of Mad Money, pointed out on Friday that the markets just experienced their worst week since early April and highlighted a mix of pressures affecting investors...
Eli Lilly and Company (LLY) Gains Approval in Australia for Early Alzheimer’s Treatment
Eli Lilly and Company (NYSE:LLY) recently announced that Australia's Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing.
Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership
On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding...
12 Best Major Stocks to Buy According to Billionaires
The U.S. stock market had one of the worst starts, at least the worst start to a presidency since 1928.
13 Stocks on Jim Cramer’s Radar Recently
On Monday's episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even in times of uncertainty.
Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now
Domestic manufacturing in the pharmaceutical industry has fallen considerably in the last decades, with most active ingredient production moving to China and other countries.
10 Best Income Stocks to Invest in Now
Amid concerns over trade restrictions and a weakening economy, some investors are seeking stability in dividend-paying stocks—a traditional defensive strategy.
Eli Lilly and Company (LLY): A Bull Case Theory
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY.
Eli Lilly and Company (NYSE:LLY) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q1 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.
15 Best Growth Stocks to Buy for the Next 3 Years
On April 29, Dan Ives of Wedbush Securities joined 'Power Lunch' on CNBC to discuss his outlook for the tech sector and expressed that tariffs aren't stopping the AI revolution...
How Did Jim Cramer’s 12 Bold Predictions Play Out?
During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence in artificial intelligence stocks, three months after the emergence of DeepSeek, a Chinese...
Jim Cramer’s Game Plan for This Week: 16 Stocks in Focus
On Friday, Mad Money host Jim Cramer took a close look at what he called one of the most important stretches of the earnings season, which came alongside major economic developments...
